Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to $1.2 billion.

  • Ultragenyx Pharmaceutical's Total Liabilities fell 86.53% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year decrease of 86.53%. This contributed to the annual value of $1.2 billion for FY2024, which is 210.27% up from last year.
  • According to the latest figures from Q3 2025, Ultragenyx Pharmaceutical's Total Liabilities is $1.2 billion, which was down 86.53% from $1.1 billion recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's Total Liabilities' 5-year high stood at $1.2 billion during Q4 2024, with a 5-year trough of $540.3 million in Q2 2021.
  • Moreover, its 5-year median value for Total Liabilities was $1.2 billion (2023), whereas its average is $991.4 million.
  • In the last 5 years, Ultragenyx Pharmaceutical's Total Liabilities crashed by 1295.09% in 2021 and then skyrocketed by 10859.89% in 2022.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Total Liabilities (Quarter) stood at $599.8 million in 2021, then skyrocketed by 98.88% to $1.2 billion in 2022, then increased by 1.9% to $1.2 billion in 2023, then increased by 2.1% to $1.2 billion in 2024, then fell by 5.39% to $1.2 billion in 2025.
  • Its Total Liabilities stands at $1.2 billion for Q3 2025, versus $1.1 billion for Q2 2025 and $1.2 billion for Q1 2025.